4-Methylumbelliferone triggers early oxidative stress, bioenergetic rewiring, and remodeling of cell-surface N-glycosylation in glioblastoma cells
Abstract
Glioblastoma (GBM) is an aggressive brain tumor characterized by high metabolic plasticity and resistance to standard therapies. Targeting metabolic vulnerabilities has emerged as a promising therapeutic strategy. 4-Methylumbelliferone (4MU), a known inhibitor of hyaluronan synthesis, has demonstrated antitumor effects beyond its canonical mechanism; however, its impact on tumor metabolism and associated pathways in GBM remains poorly understood. Human glioblastoma cell lines (U251 and LN229) were treated with 4MU (1000 µM) or vehicle. Metabolic alterations were assessed using 1H -NMR-based untargeted metabolomics, followed by exploratory metabolite set quantitative enrichment analysis (QEA) to evaluate pathway-level associations. Oxidative stress was evaluated using a dihydrorhodamine (DHR) assay. N-glycosylation patterns were analyzed by lectin-binding assays and flow cytometry. Glycolytic activity was determined using a Seahorse Glycolysis Stress Test. Statistical analyses included Student’s t-test, one-way ANOVA, and multiple comparison tests, considering p < 0.05 as significant. 4MU rapidly induced oxidative stress in both glioblastoma cell lines, detectable as early as 1.5 h. This early redox imbalance preceded broader metabolic alterations observed at 24 h. Metabolomic profiling identified significant depletion of NAD ⁺ and shifts in nucleotide-sugar precursors. Exploratory QEA highlighted coordinated associations with glycan and amino-sugar pathways, which were functionally corroborated by altered cell-surface N-glycan profiles (lectin-binding assays). Additionally, 4MU treatment increased glycolytic activity and capacity in U251 cells, pointing to a compensatory bioenergetic response in this model. These findings indicate that 4MU elicits a rapid redox imbalance alongside pronounced metabolic rewiring (characterized by NAD⁺ depletion, altered glycolytic activity, and disrupted N-glycosylation) in glioblastoma cells. Rather than a purely linear causal chain, our data suggest a multi-tiered stress response where direct UDP-sugar consumption and early oxidative stress converge to impair tumor cell bioenergetics and glycosylation patterns. Our results provide new mechanistic insights into the antitumor activity of 4MU and support its potential repositioning as a strategy targeting metabolic vulnerabilities in GBM.
Related
- Iron Chelation Therapy in Iron Overload Disorders: A Systematic Review with Narrative Synthesis of Bioenergetic Dysfunction, Oxidative Stress, and Biomarker-Guided Management.
- Aquaporin-4 Regulates Edema, Sustains Astrocyte Differentiation, and Constrains Immunosuppressive Remodeling in Glioblastoma
- Integrated Metabolomics Identifies Mitochondrial Dysfunction, Oxidative Membrane Remodeling, and Reduced Lipophilic Antioxidant Defenses in First-Episode Simple Dysmood Disorder
- Rasagiline suppresses glioblastoma cell survival through oxidative stress-mediated modulation of TLR4/NF-Κb signaling and apoptosis
- Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells.
BibTeX
@article{poodts20264methylumbelliferone,
title = {{4-Methylumbelliferone triggers early oxidative stress, bioenergetic rewiring, and remodeling of cell-surface N-glycosylation in glioblastoma cells}},
author = {Daniela Poodts and Leonardo Pellizza and Martín Manuel Ledesma and Magalí Gretel Ferreira and Facundo Núñez and Candela Miraglia and Paloma Gueller and Nicolás Seveso and Silvia Elvira Hajos and Mariano Gabri and Martín Arán and Silvina Laura Lompardía and Matías Arturo Pibuel},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73033-5},
url = {https://www.nature.com/articles/s41598-026-73033-5},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - 4-Methylumbelliferone triggers early oxidative stress, bioenergetic rewiring, and remodeling of cell-surface N-glycosylation in glioblastoma cells
AU - Daniela Poodts
AU - Leonardo Pellizza
AU - Martín Manuel Ledesma
AU - Magalí Gretel Ferreira
AU - Facundo Núñez
AU - Candela Miraglia
AU - Paloma Gueller
AU - Nicolás Seveso
AU - Silvia Elvira Hajos
AU - Mariano Gabri
AU - Martín Arán
AU - Silvina Laura Lompardía
AU - Matías Arturo Pibuel
PY - 2026
DA - 2026/10/05
JO - Scientific Reports
DO - 10.1038/s41598-026-73033-5
UR - https://www.nature.com/articles/s41598-026-73033-5
AB - Glioblastoma (GBM) is an aggressive brain tumor characterized by high metabolic plasticity and resistance to standard therapies. Targeting metabolic vulnerabilities has emerged as a promising therapeutic strategy. 4-Methylumbelliferone (4MU), a known inhibitor of hyaluronan synthesis, has demonstrated antitumor effects beyond its canonical mechanism; however, its impact on tumor metabolism and associated pathways in GBM remains poorly understood. Human glioblastoma cell lines (U251 and LN229) were treated with 4MU (1000 µM) or vehicle. Metabolic alterations were assessed using _ ^1H -NMR-based untargeted metabolomics, followed by exploratory metabolite set quantitative enrichment analysis (QEA) to evaluate pathway-level associations. Oxidative stress was evaluated using a dihydrorhodamine (DHR) assay. N-glycosylation patterns were analyzed by lectin-binding assays and flow cytometry. Glycolytic activity was determined using a Seahorse Glycolysis Stress Test. Statistical analyses included Student’s t-test, one-way ANOVA, and multiple comparison tests, considering p < 0.05 as significant. 4MU rapidly induced oxidative stress in both glioblastoma cell lines, detectable as early as 1.5 h. This early redox imbalance preceded broader metabolic alterations observed at 24 h. Metabolomic profiling identified significant depletion of NAD ⁺ and shifts in nucleotide-sugar precursors. Exploratory QEA highlighted coordinated associations with glycan and amino-sugar pathways, which were functionally corroborated by altered cell-surface N-glycan profiles (lectin-binding assays). Additionally, 4MU treatment increased glycolytic activity and capacity in U251 cells, pointing to a compensatory bioenergetic response in this model. These findings indicate that 4MU elicits a rapid redox imbalance alongside pronounced metabolic rewiring (characterized by NAD⁺ depletion, altered glycolytic activity, and disrupted N-glycosylation) in glioblastoma cells. Rather than a purely linear causal chain, our data suggest a multi-tiered stress response where direct UDP-sugar consumption and early oxidative stress converge to impair tumor cell bioenergetics and glycosylation patterns. Our results provide new mechanistic insights into the antitumor activity of 4MU and support its potential repositioning as a strategy targeting metabolic vulnerabilities in GBM.
SN - 2045-2322
ER -